Switch theme
Sign up to access all valuation multiples
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
1999
181
LTM Revenue $55.0M
LTM EBITDA $22.5M
$149M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Innate Pharma has a last 12-month revenue (LTM) of $55.0M and a last 12-month EBITDA of $22.5M.
In the most recent fiscal year, Innate Pharma achieved revenue of $14.2M and an EBITDA of -$52.7M.
Innate Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Innate Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $55.0M | XXX | $14.2M | XXX | XXX | XXX |
| Gross Profit | $55.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $22.5M | XXX | -$52.7M | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | -372% | XXX | XXX | XXX |
| EBIT | -$8.8M | XXX | -$57.9M | XXX | XXX | XXX |
| EBIT Margin | -16% | XXX | -409% | XXX | XXX | XXX |
| Net Profit | -$27.7M | XXX | -$55.6M | XXX | XXX | XXX |
| Net Margin | -50% | XXX | -392% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Innate Pharma's stock price is EUR 2 (or $2).
Innate Pharma has current market cap of EUR 183M (or $205M), and EV of EUR 133M (or $149M).
See Innate Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $149M | $205M | XXX | XXX | XXX | XXX | $-0.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Innate Pharma has market cap of $205M and EV of $149M.
Innate Pharma's trades at 10.5x EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate Innate Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Innate Pharma has a P/E ratio of -7.4x.
See valuation multiples for Innate Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $205M | XXX | $205M | XXX | XXX | XXX |
| EV (current) | $149M | XXX | $149M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBITDA | 6.6x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | -17.0x | XXX | -2.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.4x | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | 1.5x | XXX | -18.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInnate Pharma's last 12 month revenue growth is 108%
Innate Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Innate Pharma's rule of 40 is 105% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Innate Pharma's rule of X is 312% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Innate Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 108% | XXX | 208% | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | -372% | XXX | XXX | XXX |
| EBITDA Growth | 242% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 105% | XXX | -263% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 312% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 412% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 509% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innate Pharma acquired XXX companies to date.
Last acquisition by Innate Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Innate Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Innate Pharma founded? | Innate Pharma was founded in 1999. |
| Where is Innate Pharma headquartered? | Innate Pharma is headquartered in France. |
| How many employees does Innate Pharma have? | As of today, Innate Pharma has 181 employees. |
| Who is the CEO of Innate Pharma? | Innate Pharma's CEO is Mr. Jonathan Elliott Dickinson, B.Sc. ,M.B.A.. |
| Is Innate Pharma publicy listed? | Yes, Innate Pharma is a public company listed on PAR. |
| What is the stock symbol of Innate Pharma? | Innate Pharma trades under IPH ticker. |
| When did Innate Pharma go public? | Innate Pharma went public in 2006. |
| Who are competitors of Innate Pharma? | Similar companies to Innate Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Innate Pharma? | Innate Pharma's current market cap is $205M |
| What is the current revenue of Innate Pharma? | Innate Pharma's last 12 months revenue is $55.0M. |
| What is the current revenue growth of Innate Pharma? | Innate Pharma revenue growth (NTM/LTM) is 108%. |
| What is the current EV/Revenue multiple of Innate Pharma? | Current revenue multiple of Innate Pharma is 2.7x. |
| Is Innate Pharma profitable? | Yes, Innate Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Innate Pharma? | Innate Pharma's last 12 months EBITDA is $22.5M. |
| What is Innate Pharma's EBITDA margin? | Innate Pharma's last 12 months EBITDA margin is 41%. |
| What is the current EV/EBITDA multiple of Innate Pharma? | Current EBITDA multiple of Innate Pharma is 6.6x. |
| What is the current FCF of Innate Pharma? | Innate Pharma's last 12 months FCF is $96.9M. |
| What is Innate Pharma's FCF margin? | Innate Pharma's last 12 months FCF margin is 176%. |
| What is the current EV/FCF multiple of Innate Pharma? | Current FCF multiple of Innate Pharma is 1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
